key: cord-0913309-1iyeq618
authors: Jones, Madison E.; Kohn, Alison H.; Pourali, Sarah P.; Rajkumar, Jeffrey R.; Gutierrez, Yasmin; Yim, Rebecca M.; Armstrong, April W.
title: The Use of Biologics During the COVID-19 Pandemic
date: 2021-06-01
journal: Dermatol Clin
DOI: 10.1016/j.det.2021.05.010
sha: 08892cb1e5279de391e9db4af8cea4edfa936b18
doc_id: 913309
cord_uid: 1iyeq618

During the COVID-19 pandemic, there has been considerable discussion regarding the use of biologics in patients with inflammatory skin conditions, such as psoriasis, hidradenitis suppurativa, and atopic dermatitis. This article discusses clinical trial data, real world evidence, and guidelines and recommendations for biologics that inhibit TNF, IL-12/23, IL-17, IL-23, and IL-4/13 during the COVID-19 pandemic. Across these inflammatory skin conditions, existing data generally suggest that biologics do not appear to increase the risk of COVID-19 infection nor worsen COVID-19 outcomes. The impact of biologics on COVID-19 is an area of active exploration.

inhibiting TNF-α, a pro-inflammatory cytokine, effectively reducing the downstream surge in inflammation seen in psoriasis. 3 Several studies have investigated the effect of TNF-inhibitors on COVID-19 susceptibility. In order to assess this effect, a meta-analysis used data from previous clinical trials to extrapolate the potential risk of a medication based on its respiratory tract infection (RTI) rate when compared to placebo. 4 The data included reported findings from phase 3 pivotal trials for adalimumab, infliximab, etanercept, and certolizumab. 4 The meta-analysis found that there was no significant risk of RTI in TNF-inhibitors compared to placebo (OR 1.06, 95% CI 0.81-1.40; P = .55). 4 Observational studies have gathered real-world data to assess the effect of TNF-inhibitors on COVID-19. A prospective case series in New York assessed 86 patients with known immunemediated inflammatory disease (IMID) who were receiving biologics or other immunomodulatory therapies when they contracted COVID-19. 5 The level of patient care required to treat COVID-19 was then characterized by capturing if the patients were hospitalized or received only outpatient care. Importantly, this study found that the incidence rate for COVID-19 hospitalization among patients with IMID was consistent with the general population. 5 Furthermore, TNF-inhibitors were not associated with increased odds of COVID-19 hospitalization (OR 0.15, 95% CI, 0.02-1.12). 5 Similarly, a retrospective cohort study based in Detroit assessed 213 patients with IMID who were receiving treatment with immunosuppressive therapies during the COVID-19 pandemic. 6 This study found that the IMID cohort receiving immunosuppressive treatment had similar odds of COVID-19 infection, hospitalization, need for invasive ventilation, and mortality, compared to the general population. 6 Furthermore, biologics J o u r n a l P r e -p r o o f actually predicted a decreased rate of hospitalization (OR, 0.26; 95% CI, 0.066-0.95), which was driven by anti-TNF monotherapy (OR, 0.16; 95% CI, 0.032-0.72). 6 Together, the current clinical trial and real-world data suggest that patients on TNFinhibitors do not appear to increase patients' risk of contracting SARS-CoV-2, and when infected, patients do not appear to experience worsened COVID-19 outcomes compared to the general population. Additional recommendations by U.S. and international organizations for biologics used in psoriasis are provided later in the section "Summary of Recommendations" and outlined in Table 1 . The American Academy of Dermatology (AAD) also provides non-disease specific guidance for the use of systemic medications in dermatology. 7

There is currently only one FDA-approved biologic for psoriasis and PsA that inhibits IL-12/23, which is ustekinumab. Ustekinumab works by binding to the p40 protein subunit used by both IL-23 and IL-12. 3 Ustekinumab disrupts IL-23 and IL-12 mediated signaling of Th17 and Th1 pathways, thereby reducing the feedforward inflammatory mechanism in psoriasis. 3 To help inform the impact of IL-12/23 inhibitors on COVID-19 susceptibility, a metaanalysis using phase 3 clinical trial evaluated the risk of RTIs in patients with autoimmune disease on IL-12/23 and IL-23 inhibitors compared to those on placebo. 8 The analysis Real-world data also suggests that IL-12/23 inhibitors may be used safely during the COVID-19 pandemic. 5 In the New York-based case series examining IMID patients, ustekinumab was not associated with increased rates of COVID-19 hospitalization (OR 0.86; 95% CI, 0.65-1.15). 5

Together, the current clinical trial and real-world data suggest that patients on IL-12/23 inhibitors do not appear to increase patients' risk of contracting SARS-CoV-2, and when infected, patients do not appear to experience worsened COVID-19 outcomes compared to the general population. Additional recommendations are provided later in the section "Summary of Recommendations" and outlined in Table 1 .

The IL-17 inhibitors currently FDA-approved to treat psoriasis and PsA include secukinumab and ixekizumab. Brodalumab is FDA-approved for psoriasis, and it is also approved in other countries for PsA. By inhibiting IL-17, these medications mitigate the downstream inflammatory response in psoriasis. 3 While IL-17 is not a key contributor to viral clearance, it is important to understand the impact of IL-17 inhibition in the context of COVID-

A meta-analysis using pivotal clinical trial data for secukinumab, ixekizumab, and brodalumab assessed the risk of RTIs in patients on IL-17 inhibitors compared to placebo. 9 The study found an increased risk of RTIs in patients receiving IL-17 inhibitors compared to placebo (OR 1.56, 95% CI 1.04-2.33). 9 However, this study noted that evaluating the risk of RTI in clinical trials is difficult because the diagnosis of RTI is made clinically, without objective testing. 9 Therefore, the etiology of RTI symptoms is unknown and could be viral, bacterial, or J o u r n a l P r e -p r o o f allergic. This study suggested that further evaluation is needed to understand the impact of IL-17 on RTIs in the setting of the COVID-19 pandemic. 9

Real-world data suggests that patients on IL-17 inhibitors do not experience worsened COVID-19 disease severity compared to the general population. 5 This is demonstrated by the New York-based case series findings that IMID patients taking IL-17 inhibitors do not have increased odds of COVID-19 hospitalization compared to the general population (OR 0.48; 95% CI 0.03-1.23). 5

Together, the current clinical trial and real-world data suggest that patients on IL-17 inhibitors do not appear to increase patients' risk of contracting SARS-CoV-2, and when infected, patients do not appear to experience worsened COVID-19 outcomes compared to the general population. Additional recommendations are provided later in the section "Summary of Recommendations" and outlined in Table 1 .

The IL-23 inhibitors currently FDA-approved to treat psoriasis include guselkumab, tildrakizumab, and risankizumab. Guselkumab is also FDA-approved for PsA. IL-23 plays a central role in maintaining Th17 cells. Although IL-23 is not a key contributor to antiviral response, due to its effect on mucosal immunity, it is important to understand IL-23 inhibition in the context of COVID-19 infection. 8

As previously mentioned, a meta-analysis of pivotal clinical trial data investigated the impact of IL-12/23 and IL-23 antagonists on COVID-19 susceptibility. This meta-analysis found that IL-12/23 and IL-23 antagonists increased the risk of URTIs, but they did not increase the risk of viral URTIs. 8 When evaluated alone, IL-23 antagonists did not increase the risk of viral URTIs (OR 1.15, 95% CI 0.88-1.49). 8

Real-world data corroborates the safe usage of IL-23 inhibitors during the pandemic. In the New York prospective case series of IMID patients, IL-23 blockers were not associated with increased hospitalization compared to the general population (OR 0.75, 95% CI 0.50-1.12). 5

Together, the current clinical trial and real-world data suggest that patients on IL-23 inhibitors do not appear to increase patients' risk of contracting SARS-CoV-2, and when infected, patients do not appear to experience worsened COVID-19 outcomes compared to the general population. Additional recommendations are provided later in the section "Summary of Recommendations" and outlined in Table 1 .

Several studies investigating the impact of psoriasis biologics on COVID-19 do not delineate results by the different biologic classes, and instead group the results of biologics together as a whole. In one study, two Italian provinces collected data from telemedicine visits in 246 psoriasis patients on biologic or small-molecule therapy. 10 Only one patient tested positive for COVID-19, and this patient remained asymptomatic. 10 The study concluded that psoriasis (whether treated by biologic or small-molecule therapy or not) does not confer a higher risk of COVID-19 infection. 10 A separate study in Verona, Italy compared the risk of hospitalization or death due to COVID-19 in 980 psoriasis patients on biologics versus the general population of Verona. 11 The study found psoriasis patients on biologics did not have increased rates of hospitalization and death compared to the general population. 11 A global registry-based study investigated the impact of biologics on COVID-19 outcomes in psoriasis patients. 12 Out of 374 psoriasis patients with confirmed or suspected COVID-19, 71% were receiving a biologic, 18%

were receiving a nonbiologic, and 10% were not receiving any systemic treatment for psoriasis. 12 J o u r n a l P r e -p r o o f

The study found that hospitalization was more frequent in patients using nonbiological therapy than in those using biologics (OR 2.84, 95% CI 1.31-6.18). 12

In order to provide evidence-based guidelines on psoriasis management during the pandemic, the National Psoriasis Foundation (NPF) in the U.S. established a COVID-19 Task

Force. This task force issued guidelines that are a "living" resource and are amended when necessary by the rapidly evolving science of COVID-19. 13 We provide a summary of these guidelines ( Table 1 ). The NPF guidelines state that existing data generally suggest that psoriatic therapies do not meaningfully alter the risk of acquiring COVID-19 infection or having worse COVID-19 outcomes. For psoriasis patients who are not infected with COVID-19, the NPF recommends continuing biologic therapies. In addition, patients and physicians are encouraged to undergo shared decision-making to guide discussions about biologic use during the pandemic.

If a psoriasis patient becomes infected with COVID-19, the NPF recommends that patients monitor their symptoms and discuss treatment management with their physicians. If the decision is made to hold biologics during infection, the resumption of biologics should be decided on a case-by-case basis. In general, most patients can resume their psoriasis biologic after complete resolution of COVID-19 symptoms. 13 The International Psoriasis Council (IPC) provides similar guidelines as the NPF (Table   1 ). 14 However, for a patient who has active COVID-19 infection, the IPC recommends discontinuing biologics. 14

The only biologic currently FDA-approved to treat hidradenitis suppurativa (HS) is adalimumab. When the TNF-α inhibitor, adalimumab, is used to treat HS, it is administered every week, compared to the once every two-week frequency for psoriasis indication in adults.

Based on data from phase 3 pivotal trials in HS, the rates of respiratory infection in HS patients on adalimumab were similar to those on placebo. 15, 16 Observational studies have also investigated the impact of adalimumab on HS patients during the COVID-19 pandemic. In Northern Italy, a retrospective study of 96 patients with HS on systemic therapy was conducted; 48% of these patients were on adalimumab. 17 In this study, there were no cases of hospitalization or deaths from COVID-19 in HS patients. 17 This was particularly significant, given HS patients are generally burdened by metabolic and cardiovascular comorbidities. Similarly, a retrospective study in Southern Italy observed 93 HS patients on systemic therapy; 80% of these patients were on adalimumab. 18 In this study, there were no formally reported COVID-19 cases; only one patient reported COVID-19 symptoms, which spontaneously resolved. 18 In addition to these completed observational studies, an ongoing global registry has been developed to monitor and report outcomes of COVID-19 in HS patients. 19 Using the most recent COVID-19 data, the North America-based Hidradenitis Suppurativa Foundation (HSF) assembled recommendations to guide HS clinical management during the pandemic. 20 We offer a summary of these important guidelines ( 

For the treatment of atopic dermatitis (AD), dupilumab is the only biologic currently FDA-approved. Dupilumab is an IL-4-α receptor antagonist that inhibits IL-4 and IL-13 signaling. IL-4 is critical in mediating type 2 T-helper (Th2) cell polarization and humoral immunity. 22

A clinical trial meta-analysis investigated infection rates with dupilumab in pivotal phase 3 trials for AD. 22 This study examined rates of overall infection, URTI, and nasopharyngitis.

Across these three infection categories, the rate of infection was not increased in dupilumabtreated patients compared with placebo. 22

Several case reports have examined the effect of dupilumab on the clinical course and outcomes of AD patients with COVID-19. In two of these cases, the patients who tested COVID-19 positive became symptomatic and were continued on dupilumab. 23 One patient experienced a mild course of the disease and recovered without complications. 23 The other patient developed interstitial pneumonia, but recovered after 10 days; this patient's spouse (who was not on dupilumab) also contracted COVID-19 and developed interstitial pneumonia, but passed away. 23 J o u r n a l P r e -p r o o f A third case report features a high-risk patient (age >65) who tested positive for 9 consecutive weeks, but remained asymptomatic. This patient was continued on dupilumab during the period he tested positive. 24 Researchers have theorized about the potential benefits of using dupilumab in patients with COVID-19. In fatal COVID-19 cases, excess Th2 cytokines have been observed. 25 The rise in IL-4, and thus Th2, during COVID-19 illness could worsen the hyperinflammatory response. 25 Therefore, IL-4 inhibition might be beneficial. In addition, IL-6 plays a large role in the "cytokine storm" which causes lung damage in COVID-19 patients. 26 IL-6 shifts the Th1/Th2 balance towards the Th2 direction. 26 Differentiation of Th2 by IL-6 is dependent on production of IL-4, whose activity is reduced by dupilumab. 26 however, these recommendations are not specific to atopic dermatitis. 7

The International Eczema Association (IEC) has issued guidelines specific for AD management during the COVID-19 pandemic (Table 3) . 27 For patients with no infection, or who are asymptomatic or mildly symptomatic, the IEC recommends continuing biologic treatment. J o u r n a l P r e -p r o o f 

Biologics increase the risk of SARS-CoV-2 infection and hospitalization, but not ICU admission and death: real-life data from a large cohort during RED-ZONE declaration

COVID-19: risk for cytokine targeting in chronic inflammatory diseases?

Clinical Presentation, and Treatment of 13

National Psoriasis Foundation COVID-19

Task Force Guidance for Management of Psoriatic Disease During the Pandemic: Version 1

Adalimumab for treatment of hidradenitis suppurativa during the COVID-19 pandemic: Safety considerations

Two phase 3 trials of adalimumab for hidradenitis suppurativa

Moderate to severe hidradenitis suppurativa under systemic therapy during the COVID-19 outbreak

Biologics for patients affected by Hidradenitis suppurativa in the COVID-19 era: data from a referral centre of Southern Italy

J o u r n a l P r e -p r o o f